Speech Language Pathology Fellowship - Communication Aids and Systems Clinic (CASC), Waisman Center, University of Wisconsin-Madison, Madison, WI

Posted: Tuesday, January 26, 2021


Title: Speech Language Pathology, Clinical Fellow

Degree and area of specialization: Masters degree in speech language pathology with relevant experience in augmentative and alternative communication (AAC) and developmental disabilities.

License/certification: Must be eligible for temporary licensure in the State of Wisconsin. This is a mentored clinical fellowship in accordance with ASHA standards for obtaining a Certificate of Clinical Competence.

Term: This is a 12-month position.

Appointment Percent: 100%

Position Summary:

The Waisman Center is dedicated to the advancement of knowledge about human development, developmental disabilities, and neurodegenerative diseases throughout the lifespan. One of 14 centers of its kind in the United States, the Waisman Center encompasses laboratories for biomedical and behavioral research, a brain imaging center, and a clinical bio-manufacturing facility for the production of pharmaceuticals for early stage human clinical trials. In addition to its research efforts, the Center provides an array of services to people with developmental disabilities, offers numerous educational and outreach programs to young children and their families, and trains scientists and clinicians who will serve our nation in the future.

The Communication Aids and Systems Clinic (CASC) is one of 13 specialty clinics within the Waisman Center. CASC provides augmentative and alternative communication (AAC) evaluation and treatment services to children and adults with complex communication needs across the lifespan. Furthermore, CASC is affiliated with the University of Wisconsin Hospitals and Clinics (UWHC) and provides inpatient consultations within the area of AAC at both UWHC and the American Family Children's Hospital (AFCH).

The CASC Clinical Fellowship is a 12-month position in which candidates receive training and mentorship specifically within the area of AAC. The clinical fellow (CF) will have the opportunity to complete outpatient AAC evaluations and treatment for individuals across the lifespan and who have a range of diagnoses (e.g., Rett syndrome, autism spectrum disorder, genetic syndromes, ALS, and aphasia).  The CF will also complete inpatient consultations for children and adults who require AAC to meet their acute communication needs. Lastly, the CF will participate in the Wisconsin Leadership Education in Neurodevelopmental and Related Disabilities Program (WI-LEND) program, to further advance his or her leadership skills across clinical service, research, dissemination, teaching and advocacy.

Principle Duties:

70%- Provide Direct Service

  • Provide life-span outpatient diagnostic and treatment services and inpatient consults for individuals who would benefit from AAC.
  • Complete paperwork as required by funding agencies for needed services and AAC equipment.
  • May include participation in providing speech-language pathology services in other Waisman Center clinics.

30% - Completion of the Leadership Education in Neurodevelopmental and Related Disabilities (LEND) Program

  • Completion of either the 1st of 2nd year WI-LEND curriculum depending on prior experience. (Of note, the WI-LEND program runs in conjunction with the academic year from August 2021-May 2022.
  • Contribute to State capacity building through assisting in the ECHO AAC project.
  • Engage in knowledge dissemination through local, state and national conventions, as appropriate.

How to apply: To be considered, please send a cover letter and resume detailing your interest and qualifications to Sarah Marshall at [email protected].

Additionally, interested applicants will need to complete the Wisconsin LEND application (found here: https://wilend.waisman.wisc.edu/apply/) and submit directly to Sarah Marshall. Please contact Sarah Marshall at 608-263-7726 with questions.

To ensure consideration, applications must be received by: 2/26/2021.